Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149

Resistance to platinum-based chemotherapy becomes a major obstacle in non-small-cell lung cancer (NSCLC) treatment. Overexpression of the excision repair cross-complementing 1 (ERCC1) gene is reported to negatively influence the effectiveness of cisplatin-based therapy for NSCLC cells. In this study...

Full description

Bibliographic Details
Main Authors: Yuwen He, Danyang Chen, Yanmei Yi, Shanshan Zeng, Shuang Liu, Pan Li, Hui Xie, Pengjiu Yu, Guanmin Jiang, Hao Liu
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
NSCLC
HDACi
cisplatin resistance
ERCC1
miR-149
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300644

Similar Items

Similar Items